Period:
Draw Mode:
| Volume | 2,802,841 |
|
|||||
| News | - | ||||||
| Day High | 1.40 | Low High |
|||||
| Day Low | 1.2933 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| eFFECTOR Therapeutics Inc | EFTR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.0216 | 1.62% | 1.3516 | 19:58:26 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.30 | 1.2933 | 1.40 | 1.38 | 1.33 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,366 | 2,802,841 | $ 1.37 | $ 3,828,457 | - | 0.3378 - 1.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:52 | 95 | $ 1.39 | USD |
eFFECTOR Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 57.31M | 42.40M | 21.37M | $ - | $ - | -0.24 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 2.11M | 0.10% |
eFFECTOR Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EFTR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.05 | 1.48 | 1.00 | 1.24 | 5,080,514 | 0.3016 | 28.72% |
| 1 Month | 0.55 | 1.48 | 0.4665 | 0.8855065 | 4,753,982 | 0.8016 | 145.75% |
| 3 Months | 0.3946 | 1.48 | 0.3378 | 0.8564763 | 1,660,392 | 0.957 | 242.52% |
| 6 Months | 0.4033 | 1.48 | 0.3378 | 0.7905052 | 950,126 | 0.9483 | 235.14% |
| 1 Year | 1.70 | 1.99 | 0.3378 | 0.7424296 | 794,032 | -0.3484 | -20.49% |
| 3 Years | 19.00 | 40.42 | 0.3378 | 7.72 | 678,076 | -17.65 | -92.89% |
| 5 Years | 19.00 | 40.42 | 0.3378 | 7.72 | 678,076 | -17.65 | -92.89% |
eFFECTOR Therapeutics Description
| eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California. |